Esketamine for Treatment Resistant MDD


The purpose of this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 milligram (mg) and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with treatment resistant depression (TRD), as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Day 1 (prerandomization) to the end of the 4-week double-blind treatment phase (Day 28).

Inclusion Criteria:

  • Adults, ages 18-65
  • Diagnostic criteria for single-episode MDD or recurrent MDD, without psychotic features, treatment-resistant to standard antidepressants


Courtney Vecera